• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2007 Fiscal Year Final Research Report Summary

Significance of inflammatory mediators in hepatocellular carcinoma

Research Project

Project/Area Number 18591525
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionJikei University School of Medicine

Principal Investigator

ISHII Yuji  Jikei University School of Medicine, School of Medicine, Medical department Assistant Professor (40212831)

Co-Investigator(Kenkyū-buntansha) OBATA Toru  Jikei University, School of Medicine, Medical department, Associate Professor (80119776)
SHIBA Hiroaki  Jikei University, School of Medicine, Medical department, Research Associate (40366240)
ITO Ryusuke  Jikei University, School of Medicine, Medical department, Research Associate (80366202)
Project Period (FY) 2006 – 2007
KeywordsEndoeenous cannahinoids / 2-AG / HMGB-1 / IL-8 / CB1 receptor / RAGE / Henatocellular carcinoma
Research Abstract

Aim and Purpose : Endogenous cannabinoids (CBs) have been confirmed to play a role as early mediators, while high mobility group box-1 (HMGB-1) is known to be a late mediator in inflammatory response with inducing various physiologic actions. The aim of this study is to clarify a relationship between various inflammatory mediators including cytokines for the development and progression of HCC. Patients and Methods : For patients with hepatocellular carcinoma (HCC:n=45), liver cirrhosis (LC:n=23) or chronic hepatitis (CH:n=10) as well as in healthy volunteers (HV, n=34), the serum levels of CBs, 2-arachidonoylglycerol (2-AG) and anandamide (AEA) were measured by high performance liquid chromatography combined mass spectrometry (LC/MS). The serum levels of HMGB-1 and 6 inflammatory cytokines were measured by an enzyme-linked immunosorbent assay (HV:n=10, CH:n=5, LC:n=7, HCC:n=17). The expression of receptors for CBs. CBIR and CB2R as well as receptor for advanced glycation end product (RAGE) were examined by immunohistochemical analyses using the resected samples of HCC (n=23). Results : In patients with HCC, the mean level of 2-AG was 15.92 ± 7.30 ng/ml, which was significantly higher than those of the other groups (p< 0.01). The serum level of IL-8 was significantly higher in the advanced HCC group (p< 0.01). The mean level of HMGB-1 in HCC group was 5.51±2.92 ng/ml, which was significantly higher than those of the other groups (p <0.01). There existed a significant correlation between 2-AG and HMGB-1 (r=0.872, P< 0.01). In the immunohistochemical analysis of I-ICC, the expressions of CB1R and RAGE correlated with dedifferentiation of HCC. Conclusions : 2-AG, CBIR, IL-8 and FIMGB-1 seem to be associated with the development and progression of HCC. Blockade of such mediators may have potential for prevention and treatment of HCC.

  • Research Products

    (8 results)

All 2008 2007

All Presentation (8 results)

  • [Presentation] Significance of inflammatory mediators in hepatocellular carcinoma2008

    • Author(s)
      Yuji Ishii
    • Organizer
      DDW(USA)AASLD
    • Place of Presentation
      San Diego USA
    • Year and Date
      2008-05-20
    • Description
      「研究成果報告書概要(和文)」より
  • [Presentation] Significance of inflammatory mediators in hepatocellular carcinoma2008

    • Author(s)
      Yuji, Ishii, et. al.
    • Organizer
      DDW (USA) AASLD
    • Place of Presentation
      San Diego, USA
    • Year and Date
      2008-05-20
    • Description
      「研究成果報告書概要(欧文)」より
  • [Presentation] Significance of CB1 cannabinoid receptor antagonism for the treatment of hepatocellular carcinoma2008

    • Author(s)
      Yuji Ishii
    • Organizer
      The 18th Conference of the Asian Pacific Associati on for the Study of the Liver
    • Place of Presentation
      Seoul
    • Year and Date
      2008-03-24
    • Description
      「研究成果報告書概要(和文)」より
  • [Presentation] Significance of CB1 cannabinoid receptor antagonism for the treatment of hepatocellular carcinoma2008

    • Author(s)
      Yuji, Ishii, et. al.
    • Organizer
      The 18th Conference of the Asian Pacific Association for the Study of the Liver
    • Place of Presentation
      Seoul
    • Year and Date
      2008-03-24
    • Description
      「研究成果報告書概要(欧文)」より
  • [Presentation] 自施設における肝細胞癌切除後の再発因子の検討および内因性カンナビノイドの意義と再発に対する治療方針2007

    • Author(s)
      石井 雄二
    • Organizer
      107回日本外科学会定期学術集会
    • Place of Presentation
      大阪
    • Year and Date
      2007-04-11
    • Description
      「研究成果報告書概要(和文)」より
  • [Presentation] Risk factors for recurrence of hepatocellular and endogenous cannabinoids2007

    • Author(s)
      Yuji, Ishii, et. al.
    • Organizer
      The 107th Annual Congress of Japan Surgical Society
    • Place of Presentation
      Osaka
    • Year and Date
      2007-04-11
    • Description
      「研究成果報告書概要(欧文)」より
  • [Presentation] Role of endogenous cannabinoidsas a novel marker of hepatocellular carcinoma2007

    • Author(s)
      Yuji Ishii
    • Organizer
      The 17th Conference of the Asian Pacific Associati on for the Study of the Liver
    • Place of Presentation
      Kyoto
    • Year and Date
      2007-03-30
    • Description
      「研究成果報告書概要(和文)」より
  • [Presentation] Role of endogenous cannabinoidsas a novel marker of hepatocellular carcinoma2007

    • Author(s)
      Yuji, Ishii, et. al.
    • Organizer
      The 17th Conference of the Asian Pacific Association for the Study of the Liver
    • Place of Presentation
      Kyoto
    • Year and Date
      2007-03-30
    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2010-02-04  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi